相关实验视频

Updated: Jul 19, 2026

Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques

Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques

Published on: March 13, 2015

基线血清EV-miR-1-3p作为HCV根除后肝细胞癌发展的保护因子和生物标志物

Wei Teng^1,2,3, Wei-Ting Ku^1,4, Po-Ting Lin^1,2

¹Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan.

Journal of translational medicine

|July 2, 2025

概括

一种新的生物标志物,细胞外囊微RNA-1-3p (EV-miR-1-3p),可以预测治疗后慢性型肝炎 (CHC) 患者的肝细胞癌 (HCC) 风险. 高的EV-miR-1-3p水平表明HCC的风险较低,病毒根除后的生存率更好.

科学领域:

肝病学和病毒性肝炎研究.
生物标志物的发现和验证.
细胞外囊泡和微RNA分析.

背景情况:

直接作用抗病毒 (DAA) 疗法有效治疗慢性型肝炎 (CHC),实现高持续病毒反应 (SVR) 率.
即使在成功根除病毒之后,肝细胞癌 (HCC) 仍然可以发展.
迫切需要可靠的生物标志物来预测SVR后患者的HCC风险.

研究的目的:

为了确定基线血清细胞外囊泡微RNAs (EV-miRNAs) 相关的HCC发展后实现SVR.
评估已识别的EV-miRNAs对HCC风险和患者存活率的预测值.

主要方法:

在发现队列中对EV-miRNA概况进行回顾性分析,该队列是获得SVR的CHC患者.
使用小RNA测序和miRNA酶免疫试验 (miREIA) 在独立队列中验证候选EV-miRNA.
与基线EV-miRNA水平相关的HCC发展,无病生存期 (DFS) 和整体生存期 (OS) 的评估.

主要成果:

在发现队列中,四种EV-miRNA (EV-miR-1-3p,EV-miR-148a-3p,EV-miR-223-3p,EV-miR-4433b-5p) 在HC和非HC组之间存在显著差异.
在验证队列中,高基线EV-miR-1-3p和EV-miR-148a-3p水平与剩余的无HCC和更长的DFS相关.
与AFP和FIB-4等已知生物标志物相比,EV-miR-1-3p对HCC发生和OS的预测准确度更高,并且与更好的肝功能相关.

结论:

基线血清EV-miR-1-3p是DAA治疗后的CHC患者中HCC风险分层的有希望的保护性生物标志物.
在这种患者群体中,EV-miR-1-3p可以预测生存结果,包括DFS和OS.
这一发现为个性化风险评估和病毒根除后的CHC患者的管理提供了一个新的工具.

关键词:

直接作用的抗病毒药物.细胞外囊泡的MiRNA 肝细胞癌是肝细胞癌.在SVR12中使用SVR12.

更多相关视频

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

相关概念视频

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...